| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $265.2M | — | +11.0% |
| Cost of Revenue | $90.5M | — | +15.7% |
| R&D Expense | $72.1M | — | +5.4% |
| SG&A Expense | $27.5M | — | +1.7% |
| Operating Income | $31.6M | — | +6.7% |
| Pre-tax Income | $29.0M | — | -17.2% |
| Income Tax | $5.9M | — | -19.9% |
| Net Income | $23.4M | — | -15.6% |
| EPS (Basic) | $0.48 | — | -14.3% |
| EPS (Diluted) | $0.47 | — | -9.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $497.4M | -48.2% | -58.1% |
| Accounts Receivable | $141.2M | -0.4% | +18.9% |
| Inventory | $95.1M | +0.7% | +5.5% |
| Current Assets | $801.0M | -37.1% | -44.9% |
| Total Assets | $1.64B | -23.1% | -20.9% |
| Current Liabilities | $155.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $50.6M | — | +110.5% |
| Capital Expenditures | $912K | — | -85.1% |
| Investing Cash Flow | $2.4M | — | +104.4% |
| Financing Cash Flow | -$518.2M | — | — |
| Free Cash Flow | $49.7M | — | +177.1% |
| -77.1% |
| Total Liabilities | $739.8M | -40.6% | -41.5% |
| Stockholders' Equity | $859.8M | +1.4% | +13.2% |